Germany Medical Cannabis Imports Surge Sixfold After 2024 Reforms

Import Volume Climbs to 50,539 kg in Q1 2026

Germany imported 50,539 kilograms of medical cannabis in the first quarter of 2026, compared to 8,143 kg in the same period two years earlier. That's a 520% increase. The surge follows the April 2024 CanG reforms, which decriminalized adult possession up to 25 grams, permitted home cultivation of three plants, and streamlined medical cannabis prescribing by removing prior-authorization requirements for most conditions.

The Q1 2026 figure translates to 111,419 pounds of flower and extract imports. Germany now accounts for roughly 60% of Europe's regulated medical cannabis volume, surpassing the Netherlands and Italy combined. Domestic cultivation remains minimal—fewer than 2,000 kg annually—so the market runs almost entirely on imports from Canada, Portugal, and Israel.

2024 Reforms Expanded Prescribing and Patient Pool

The CanG legislation removed the requirement for patients to exhaust conventional treatments before accessing cannabis, opening prescriptions to an estimated 4 million additional patients. Fewer than 200,000 Germans held active medical cannabis prescriptions before April 2024. By Q1 2026, that number exceeded 1.1 million, according to Federal Institute for Drugs and Medical Devices (BfArM) registry data.

Pharmacies no longer need case-by-case insurance approvals for chronic pain, PTSD, or chemotherapy-induced nausea. The streamlined pathway cut average prescription turnaround from 14 days to under 48 hours. Reimbursement rates remain uneven—statutory insurers cover roughly 70% of prescriptions, while private plans approve closer to 90%—but administrative friction dropped sharply.

The reforms also legalized cannabis social clubs (non-profit cultivation collectives capped at 500 members), though fewer than 300 clubs have received operating licenses as of August 2026. Most patient demand still flows through pharmacies dispensing imported product.

Supply-Chain Pressure and Pricing Dynamics

Wholesale prices for imported cannabis flower fell from €8.50 per gram in Q1 2024 to €5.20 per gram in Q1 2026 as supply scaled faster than demand. Canadian licensed producers—Aurora, Tilray, and Canopy Growth—dominate the import manifest, shipping bulk flower in 5-kg and 10-kg lots to German pharmaceutical distributors. Portuguese cultivators, led by Tilray's EU-GMP facility in Cantanhede, supply another 30% of volume.

Pharmacy retail prices dropped in parallel, from €12–15 per gram to €8–10 per gram for standard THC flower (18–22% THC). High-CBD strains and specialty genetics still command €12–14 per gram. Price compression has thinned margins for smaller importers, consolidating the market around vertically integrated MSOs with EU distribution networks.

For context on Germany's regulatory evolution, see the CannIntel topic hub on Germany's medical cannabis market.

The next supply test arrives in Q4 2026, when BfArM's domestic cultivation tender awards licenses to three German growers. Those facilities won't reach commercial harvest until late 2027, so imports will carry the market through at least 2028.